Covaxin
-
Malvern’s Ocugen Prepping for $16.5 Million Stock Sale Weeks After Nixing Its COVID Vaccine
A Malvern-based biotechnology company known for its gene therapies and vaccines, is expecting to raise $16.5 million through a public…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
